Recruiting

GLP-1

Sponsor:

Virginia Polytechnic Institute and State University

Code:

NCT07104539

Conditions

Muscle Mass

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Interventions

Strength Training

Wait first, then strength training

Study Details

Brief summary:

GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.

Conditions

Muscle Mass

Study ID

NCT07104539

Start date

Oct 8, 2025

Status verified date

Jan, 2026

Completion date

May, 2027

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Age, 50y+
  • Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
  • Weight <300 lb
  • Pass a health and exercise readiness screening

Exclusion Criteria:

  • Age <50
  • Weight >300 lb
  • Osteoporosis
  • Active metabolic, neoplastic, or cardiovascular disease
  • Unable or unwilling to provide consent

Study Design

Enrollment

30 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Strenth Training

Participants will undergo strength training 3 times per week for 14 weeks.

other: Waitlisted control

Participants will have no strength training intervention for 14 weeks. Participants will be offered the same 14-week strength training program after the initial 14 weeks.

Interventions

Strength Training

Participants taking a GLP-1 will undergo a 14-week strength training regimen to determine changes in muscle mass. They will perform a series of resistance training exercises supervised by a personal trainer on 3 days per week.

Wait first, then strength training

Participants will be waitlisted and receive the 14-week strength training intervention at the end of the waitlist period. During the waitlist period, participants will get no intervention and then be offered the strength training intervention after the first 14 weeks.

Primary outcome measure

  • Muscle mass by d3-creatine dilution [ Time Frame: Water containing creatine isotope consumed in lab; Urine sample collection on Day 0 and Day 3 at baseline and 14 weeks. ]
  • Balance testing - Percentage of failed recoveries [ Time Frame: 2-hour testing session in lab at baseline and 14 weeks. ]

Central Contacts and Locations

Central contacts

Kevin Davy

540-231-3487kdavy@vt.edu

Elaina Marinik

540-231-0923emarinik@vt.edu

Locations

Virginia Tech

Recruiting

Blacksburg, Virginia, United States, 24061

More Information

Sponsor

Virginia Polytechnic Institute and State University

Last update posted

Jan 21, 2026

Last verified

Jan, 2026

Keywords

  • Weight loss
  • GLP-1 agonist
  • Obesity
  • Lean mass
  • Body composition
  • Strength training

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Virginia Polytechnic Institute and State University on 2026-01-21.